Novo Nordisk As Stock Net Asset
| NONOF Stock | USD 111.54 4.71 4.41% |
Novo Nordisk AS fundamentals help investors to digest information that contributes to Novo Nordisk's financial success or failures. It also enables traders to predict the movement of Novo Pink Sheet. The fundamental analysis module provides a way to measure Novo Nordisk's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Novo Nordisk pink sheet.
Novo |
Novo Nordisk AS Company Net Asset Analysis
Novo Nordisk's Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Current Novo Nordisk Net Asset | 241.26 B |
Most of Novo Nordisk's fundamental indicators, such as Net Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Novo Nordisk AS is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
| Competition |
Based on the recorded statements, Novo Nordisk AS has a Net Asset of 241.26 B. This is much higher than that of the Healthcare sector and significantly higher than that of the Biotechnology industry. The net asset for all United States stocks is notably lower than that of the firm.
Novo Net Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Novo Nordisk's direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Novo Nordisk could also be used in its relative valuation, which is a method of valuing Novo Nordisk by comparing valuation metrics of similar companies.Novo Nordisk is currently under evaluation in net asset category among its peers.
Novo Fundamentals
| Return On Equity | 0.72 | |||
| Return On Asset | 0.22 | |||
| Profit Margin | 0.31 % | |||
| Operating Margin | 0.43 % | |||
| Current Valuation | 292.82 B | |||
| Shares Outstanding | 1.72 B | |||
| Shares Owned By Institutions | 38.87 % | |||
| Price To Earning | 41.24 X | |||
| Price To Book | 26.64 X | |||
| Price To Sales | 1.73 X | |||
| Revenue | 176.95 B | |||
| Gross Profit | 148.51 B | |||
| EBITDA | 76.8 B | |||
| Net Income | 55.52 B | |||
| Cash And Equivalents | 31.04 B | |||
| Cash Per Share | 13.68 X | |||
| Total Debt | 20.77 B | |||
| Debt To Equity | 0.34 % | |||
| Current Ratio | 0.94 X | |||
| Book Value Per Share | 37.10 X | |||
| Cash Flow From Operations | 78.89 B | |||
| Earnings Per Share | 3.53 X | |||
| Price To Earnings To Growth | 1.94 X | |||
| Number Of Employees | 54.39 K | |||
| Beta | 0.33 | |||
| Market Capitalization | 318.05 B | |||
| Total Asset | 241.26 B | |||
| Retained Earnings | 41.06 B | |||
| Working Capital | 9.98 B | |||
| Current Asset | 51.58 B | |||
| Current Liabilities | 41.59 B | |||
| Z Score | 9.0 | |||
| Annual Yield | 0.01 % | |||
| Five Year Return | 1.78 % | |||
| Net Asset | 241.26 B | |||
| Last Dividend Paid | 12.4 |
About Novo Nordisk Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Novo Nordisk AS's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Novo Nordisk using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Novo Nordisk AS based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Novo Pink Sheet
When determining whether Novo Nordisk AS offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Novo Nordisk's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Novo Nordisk As Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Novo Nordisk As Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novo Nordisk AS. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.